Cosmo is a speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases.
Find out more about us
Cosmo’s product portfolio strategy is focused on the treatment of diseases of the colon, primarily on Inflammatory Bowel Diseases (IBD).
The experience gained by years of manufacturing was the basis for the establishment of the MMX® technology. It allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets in a delayed and controlled extent with the effect that the pharmaceutical products can be applied to the full length of the colon.
The blend of our knowledge of the colon and the unique characteristics of the MMX® technology gives us a strong competitive edge in developing new applications for the colon without having to resort to the expensive and risky pure research process for new chemical entities.
(Delayed by 15 minutes)
+1.00 (+0.61%) 17:31 01 Dec 2015
Detailed share price
30 Oct 2015
Mochida concludes phase III trials for Lialda® in Japan and files for registration
07 Mar 2016
Full year results 2015 reporting
View desktop site